Humana delivered a better-than-expected first quarter, but Wall Street was not impressed. The health insurance giant beat earnings estimates on the back of tighter medical cost controls, then declined to raise its full-year profit outlook — a decision that stood out sharply against a backdrop of rivals who did raise their forecasts, and one that sent its shares sliding 5% in morning trading Wednesday.
For a company that has been one of the more resilient players in the Medicare Advantage space during a period of sustained industry-wide pressure, the market’s reaction reflected a specific disappointment: investors had been expecting a strong start to the year to translate into upgraded guidance, and it did not.
The numbers behind the quarter
Humana posted adjusted earnings per share of $10.31 for the first quarter, edging past the analyst consensus estimate of $10.19 according to LSEG data. The beat was driven primarily by medical costs coming in below the company’s own projections — a meaningful positive signal in an industry where cost management has become the defining challenge of the past 3 years.
The insurance segment benefit ratio — the percentage of premiums spent on medical care, and one of the most closely watched metrics in the sector — came in at 89.4% for the quarter, better than the company’s own outlook of just under 90%. A lower ratio indicates better cost efficiency, and Humana’s result pointed to real discipline in managing claims during the period.
The company also noted that both medical and pharmacy cost trends were tracking slightly better than expectations heading into the rest of the year.
Why the forecast stayed flat
Despite the encouraging quarterly performance, Humana held its annual adjusted profit forecast at a minimum of $9 per share — unchanged from previous guidance. It also lowered its reported profit forecast to at least $8.36 from a prior estimate of at least $8.89, citing the impact of Star Ratings issued by the Medicare agency. Those ratings, assigned on a scale of 1 to 5 stars, are directly tied to bonus payments that insurers receive from the federal government, and Humana’s ratings have weighed on its financial projections.
The more persistent challenge flagged by management is the widening gap between what the federal government pays private insurers for Medicare Advantage plans and what those insurers are actually spending on healthcare. The U.S. government announced earlier this month that it would raise payments to Medicare Advantage insurers by an average of 2.48% in 2027 — a step in the right direction, but one that Humana’s leadership indicated has not yet closed the gap that has been building compared to the prior year.
A market still watching costs carefully
Humana’s position in the Medicare Advantage market is notable precisely because it has continued growing membership even as larger competitors have pulled back from the segment in response to the sustained cost pressures that have defined the past 3 years. That growth is a sign of competitive strength, but it also means the company carries more exposure to the ongoing funding gap than peers who have reduced their footprint.
To manage that dynamic, Humana said it plans to adjust benefits as necessary to maintain stable margins — a standard lever for insurers navigating mismatches between premiums and costs, but one that can affect the attractiveness of plans to existing and prospective members if applied too aggressively.
What analysts are saying
Market reaction and analyst commentary following the report reflected concern about the second half of the year. Humana’s second-quarter benefit ratio is expected to rise to slightly above 91% — a step up from the first quarter’s 89.4% and a signal that cost pressures may intensify as the year progresses. That trajectory, combined with the unchanged full-year outlook, gave analysts reason to flag potential headwinds in the months ahead.
For investors who had been counting on Humana‘s strong start to justify a more optimistic full-year view, Wednesday’s guidance left that thesis unfulfilled — at least for now.
Disclaimer: This article is for informational purposes only and not financial advice. Always research before making investment decisions.
Source: Reuters